JNJ

187.02

-1.76%↓

ABT

126.54

-0.55%↓

MDT

93.57

-0.3%↓

VEEV

293.87

-0.52%↓

A

145.72

-0.61%↓

JNJ

187.02

-1.76%↓

ABT

126.54

-0.55%↓

MDT

93.57

-0.3%↓

VEEV

293.87

-0.52%↓

A

145.72

-0.61%↓

JNJ

187.02

-1.76%↓

ABT

126.54

-0.55%↓

MDT

93.57

-0.3%↓

VEEV

293.87

-0.52%↓

A

145.72

-0.61%↓

JNJ

187.02

-1.76%↓

ABT

126.54

-0.55%↓

MDT

93.57

-0.3%↓

VEEV

293.87

-0.52%↓

A

145.72

-0.61%↓

JNJ

187.02

-1.76%↓

ABT

126.54

-0.55%↓

MDT

93.57

-0.3%↓

VEEV

293.87

-0.52%↓

A

145.72

-0.61%↓

Search

Hutchison China MediTech Ltd ADR

Open

SectorHealthcare

14.71 -0.68

Overview

Share price change

24h

Current

Min

14.48

Max

14.81

Key metrics

By Trading Economics

Income

222M

227M

Sales

-23M

139M

P/E

Sector Avg

5.698

37.461

Profit margin

163.843

Employees

1,780

EBITDA

6.3M

1.3M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+30.42% upside

Market Stats

By TradingEconomics

Market Cap

-125M

2.6B

Previous open

15.39

Previous close

14.71

News Sentiment

By Acuity

50%

50%

163 / 373 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Hutchison China MediTech Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

27 paź 2025, 23:32 UTC

Acquisitions, Mergers, Takeovers

CSL Delays Flu-Vaccine Spinoff, Cuts Guidance As U.S. Vaccination Rates Decline

27 paź 2025, 23:00 UTC

Acquisitions, Mergers, Takeovers

Australia's AUB Opens Books to EQT After Receiving $3.44 Billion Takeover Offer

27 paź 2025, 21:42 UTC

Earnings

Waste Management 3Q Revenue Climbs, Sees Fiscal Year Revenue at Low End of Prior View

27 paź 2025, 23:43 UTC

Market Talk

Nikkei May Rise on Easing U.S.-China Trade Tensions -- Market Talk

27 paź 2025, 23:42 UTC

Market Talk

Gold Rises on Likely Technical Recovery -- Market Talk

27 paź 2025, 23:37 UTC

Market Talk

Investors May Cheer CSL's Decision to Delay Seqirus Spinoff -- Market Talk

27 paź 2025, 23:00 UTC

Earnings

The Good Vibes Are Back on Wall Street -- WSJ

27 paź 2025, 22:45 UTC

Acquisitions, Mergers, Takeovers

Australia's AUB Opens Books to EQT After Receiving $3.44B Takeover Offer

27 paź 2025, 22:06 UTC

Market Talk
Earnings

Nucor Expects Weaker Steel Market in 4Q -- Market Talk

27 paź 2025, 22:05 UTC

Earnings

China Southern Airlines: Continued Improvements in Business Environment Supported Results >1055.HK

27 paź 2025, 22:04 UTC

Earnings

Cadence Reports Solid Earnings. The Stock Is Falling. -- Barrons.com

27 paź 2025, 22:04 UTC

Earnings

China Southern Airlines 3Q Net CNY3.84B, Up 20.3% on Year >1055.HK

27 paź 2025, 22:03 UTC

Earnings

China Southern Airlines 3Q Rev CNY51.37B, Up 3.0% on Year >1055.HK

27 paź 2025, 21:27 UTC

Earnings

Waste Management 3Q Rev Climbs, Sees FY Rev at Low End of Prior View

27 paź 2025, 21:19 UTC

Earnings

Cadence Reports Solid Earnings. The Stock Is Falling. -- Barrons.com

27 paź 2025, 20:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

27 paź 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

27 paź 2025, 20:37 UTC

Earnings

Waste Management: Decrease From Prior Rev Expectations Is Primarily Related to Further Decline in Recycled Commodity Pricing, Modestly Lower Rev Expectations From Healthcare Solutions >WM

27 paź 2025, 20:37 UTC

Earnings

Waste Management: 2025 Free Cash Flow Guidance Remains Between $2.8B and $2.9B >WM

27 paź 2025, 20:37 UTC

Earnings

Waste Management: 2025 Total Co Rev Is Now Expected Approximately $25.275B >WM

27 paź 2025, 20:37 UTC

Earnings

Waste Management: Affirming 2025 Adjusted Operating EBITDA Guidance Between $7.475B and $7.625B >WM

27 paź 2025, 20:31 UTC

Earnings

Nucor Sees 4Q Earnings Lower Than 3Q

27 paź 2025, 20:30 UTC

Earnings

Nucor 3Q Steel Mills Total Shipments 6.43M Tons >NUE

27 paź 2025, 20:30 UTC

Earnings

Nucor 3Q EPS $2.63 >NUE

27 paź 2025, 20:30 UTC

Earnings

Nucor 3Q Net $607M >NUE

27 paź 2025, 20:30 UTC

Earnings

Nucor 3Q Sales $8.52B >NUE

27 paź 2025, 20:30 UTC

Earnings

Nucor 3Q Total Tons Shipped to Outside Customers Down 1% >NUE

27 paź 2025, 20:30 UTC

Earnings

Waste Management 3Q Adj EPS $1.98 >WM

27 paź 2025, 20:30 UTC

Earnings

Waste Management 3Q Rev $6.44B >WM

27 paź 2025, 20:30 UTC

Earnings

Waste Management 3Q Net $603M >WM

Peer Comparison

Price change

Hutchison China MediTech Ltd ADR Forecast

Price Target

By TipRanks

30.42% upside

12 Months Forecast

Average 19.38 USD  30.42%

High 25 USD

Low 13.75 USD

Based on 2 Wall Street analysts offering 12 month price targets forHutchison China MediTech Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

2 ratings

1

Buy

0

Hold

1

Sell

Technical Score

By Trading Central

14.24 / 14.78Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

163 / 373 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
help-icon Live chat